PRLX 93936

Drug Profile

PRLX 93936

Alternative Names: Erastin analogue; PRLX 82845; PRLX93936

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia University; Whitehead Institute for Biomedical Research
  • Developer Prolexys Pharmaceuticals
  • Class Quinazolinones; Small molecules
  • Mechanism of Action Ion channel modulators; Ras protein inhibitors; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 01 Mar 2012 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy) in USA (IV)
  • 01 Nov 2011 Prolexys completes a phase I trial in Advanced solid tumours in USA (NCT00528047)
  • 10 Feb 2011 Prolexys completes enrolment in its Phase I trial in Solid tumours in USA (NCT00528047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top